Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Aurinia.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Kezar stockholders will receive $6.955 in cash per share plus one contingent value right (CVR). The CVR provides rights to potential payments from the clinical development of zetomipzomib, proceeds from Kezar's collaboration with Everest Medicines and sale of its Sec61-based program to Enodia Therapeutics, and 100% of Kezar's closing net cash exceeding $50 million, net of certain expenses.

Kezar insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Kezar by imposing a significant penalty if Kezar accepts a competing bid. We are investigating the conduct of the Kezar board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.